Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0725

+3.6%

Oct 31 3:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	7/31/2014 9:08:47 AM
	Read Replies (1) of 13111

Excellent peer-reviewed PV-10 overview article by Dr. Merrick Ross ****************************************************** Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma Thursday July 31, 2014 An article entitled "Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma" was published in the Journal of Surgical Oncology, 2014;109:314-319. The article, authored by Merrick I. Ross, MD of M.D. Anderson Cancer Center in Houston, TX, discusses published results of studies that have assessed the treatment of melanoma with PV-10 and the rationale for combining its use with recently approved immunotherapeutic agents. The article is available from the Publications page on the Provectus website at www.pvct.com/publications.html .... or directly: eorder.sheridan.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next